Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Enanta Pharmaceuticals (ENTA) Invested Capital (2016 - 2025)

Enanta Pharmaceuticals filings provide 14 years of Invested Capital readings, the most recent being $126.6 million for Q4 2025.

  • On a quarterly basis, Invested Capital rose 13.21% to $126.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $126.6 million, a 13.21% increase, with the full-year FY2025 number at $64.7 million, down 49.76% from a year prior.
  • Invested Capital hit $126.6 million in Q4 2025 for Enanta Pharmaceuticals, up from $64.7 million in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $436.0 million in Q1 2021 to a low of $64.7 million in Q3 2025.
  • Median Invested Capital over the past 5 years was $227.3 million (2023), compared with a mean of $239.6 million.
  • The widest YoY moves for Invested Capital: up 13.21% in 2025, down 49.76% in 2025.
  • Enanta Pharmaceuticals' Invested Capital stood at $384.4 million in 2021, then fell by 21.74% to $300.8 million in 2022, then tumbled by 36.22% to $191.9 million in 2023, then crashed by 41.73% to $111.8 million in 2024, then rose by 13.21% to $126.6 million in 2025.
  • The last three reported values for Invested Capital were $126.6 million (Q4 2025), $64.7 million (Q3 2025), and $79.3 million (Q2 2025) per Business Quant data.